Search IPOs
Subscription Status · Jun 18 – Jun 22, 2026 · ₹196–208
The Avience Biomedicals IPO subscription has recorded exceptional investor demand with an overall subscription of 385.33× as of Jun 22, 2026, indicating that investors applied for 385.33 times the number of shares on offer. All investor categories (institutional, HNI, and retail) have participated actively, making this one of the closely watched IPO openings.
Last updated: Jun 22, 2026, 5:12 PM IST
| Category | Shares Offered | Shares Bid For | Times Subscribed | Applications |
|---|---|---|---|---|
|
QIB
Qualified Institutional Buyers
|
273,600 | 53,837,400 |
196.77×
|
172 |
|
NII
Non-Institutional Investors
|
207,000 | 123,708,000 |
597.62×
|
31,835 |
|
bNII
Bids above ₹10L
|
138,000 | 92,566,800 |
670.77×
|
16,492 |
|
sNII
Bids below ₹10L
|
69,000 | 31,141,200 |
451.32×
|
15,343 |
|
Individual
Individual Investors
|
481,200 | 193,064,400 |
401.21×
|
160,887 |
|
Total
|
961,800 | 370,609,800 |
385.33×
|
224,729 |
How subscription built up across investor categories over time
Snapshot of each day's bidding activity
| Category | Offered | Bid For | Times | Applications |
|---|---|---|---|---|
| QIB | 273,600 | - | - | - |
| NII | 207,000 | 2,779,200 | 13.43× | 750 |
| bNII | 138,000 | 1,885,200 | 13.66× | 320 |
| sNII | 69,000 | 894,000 | 12.96× | 430 |
| Individual Investors | 481,200 | 7,328,400 | 15.23× | 6,107 |
| Total | 961,800 | 10,107,600 | 10.51× | 7,607 |
| Category | Offered | Bid For | Times | Applications |
|---|---|---|---|---|
| QIB | 273,600 | 7,800 | 0.03× | 1 |
| NII | 207,000 | 13,735,800 | 66.36× | 2,711 |
| bNII | 138,000 | 9,118,800 | 66.08× | 1,143 |
| sNII | 69,000 | 4,617,000 | 66.91× | 1,568 |
| Individual Investors | 481,200 | 28,377,600 | 58.97× | 16,882 |
| Total | 961,800 | 42,121,200 | 43.79× | 22,305 |
| Category | Offered | Bid For | Times | Applications |
|---|---|---|---|---|
| QIB | 273,600 | 53,837,400 | 196.77× | 172 |
| NII | 207,000 | 123,708,000 | 597.62× | 31,835 |
| bNII | 138,000 | 92,566,800 | 670.77× | 16,492 |
| sNII | 69,000 | 31,141,200 | 451.32× | 15,343 |
| Individual Investors | 481,200 | 193,064,400 | 401.21× | 160,887 |
| Total | 961,800 | 370,609,800 | 385.33× | 224,729 |
As of June 22, 2026, the Avience Biomedicals IPO has been subscribed 385.33 times overall. The IPO is fully subscribed with strong investor demand indicating extremely high interest. A total of 224,729 applications received across all categories.
The Avience Biomedicals IPO subscription window was open from June 18, 2026 to June 22, 2026. Investors could apply through their demat account or ASBA facility.
The Avience Biomedicals IPO has a price band of ₹196 to ₹208 per share, with a lot size of 600 shares. Minimum retail investment: ₹117,600 (lower band) or ₹124,800 (upper band).
The QIB category has been subscribed 196.77 times. QIBs were offered 273,600 shares. Strong QIB subscription indicates high institutional confidence.
Overall NII: 597.62×. bNII (>₹10L): 670.77×, sNII (<₹10L): 451.32×. NII includes HNIs and corporate entities investing above ₹2 lakh.
Basis of allotment is on June 23, 2026. Check via the registrar's website, Skyline Financial Services Pvt.Ltd. using your PAN number, application number, or DP/Client ID. You can also check on BSE/NSE websites or through your broker's app.
Avience Biomedicals IPO is expected to list on June 25, 2026. Shares will list on NSE SME platform. Allotted shares are credited to your demat account 1 business day before listing.
A subscription multiple of 385.33× means investors have bid for 385.33 times the total shares available. Since the IPO is oversubscribed, not every applicant will receive shares, allotment happens via lottery (for retail) or proportionately (for other categories). Higher multiples generally reduce allotment probability.
Based on the current retail subscription of data pending, the estimated allotment probability for retail investors is Very Low. Only 1 lot likely via lottery if selected. If final subscription stays below 1×, all applicants are likely to get full allotment.
You can apply for Avience Biomedicals IPO through: (1) ASBA (Application Supported by Blocked Amount) via your bank's net banking or mobile app, (2) UPI-based application through your broker's app (Zerodha, Groww, Angel One, etc.), or (3) directly via your demat account. The amount is blocked in your account and deducted only upon allotment. Applications were accepted from Jun 18 to Jun 22, 2026.
The grey market premium (GMP) reflects unofficial pre-listing trading sentiment. For the latest Avience Biomedicals IPO GMP data, check the IPORise GMP page. Note: GMP is unofficial, speculative, and not a guaranteed indicator of listing price. Use it only as a sentiment signal alongside official subscription data.
New to reading subscription numbers? Read our guide on IPO subscription explained.
Subscription Opens Done
Jun 18, 2026Subscription Closes Done
Jun 22, 2026Basis of Allotment Done
Jun 23, 2026Listing on NSE Done
Jun 25, 2026Only 1 lot likely via lottery if selected.
Share Subscription Card
Download a branded image to share on WhatsApp, Twitter, or Telegram
Higher subscription = lower allotment probability. Progress bars compare each category relative to the highest-subscribed category.
